



Monoclonal Antibodies for the Outpatient Treatment of COVID-19 as a Pharmacy Benefit

April 1, 2022

Effective April 1, 2022, the Department of Health Care Services (DHCS) will reimburse the following monoclonal antibodies for the treatment of COVID-19 as a pharmacy benefit when dispensed for use in nonhospitalized patients in accordance with the Emergency Use Authorization (EUA) requirements or Food and Drug Administration (FDA) approval.

Monoclonal Antibodies for Pre-Exposure Prophylaxis of COVID-19

- Tixagevimab packaged with Cilgavimab and administered as two separate consecutive intramuscular injections (EUA issued December 8, 2021; updated December 20, 2021).

Monoclonal Antibodies to Treat Mild-to-Moderate COVID-19

- Sotrovimab (EUA issued May 26, 2021; updated December 16, 2021).
- Bebtelovimab (EUA issued February 11, 2022).

These monoclonal antibodies should be administered in either a hospital or a health care setting with immediate access to medications to treat a severe infusion or hypersensitivity reaction (i.e., anaphylaxis) and can activate the emergency medical system (EMS) if necessary.

- DHCS allows a broad range of providers and suppliers to administer these treatments, including, but not limited to, the following:
 - Freestanding and hospital-based infusion centers
 - Home health care agencies
 - Nursing homes
 - Entities with whom nursing homes contract to administer treatment

Important Billing Instructions

- Dispensing is restricted to the requirements of the EUA or FDA approval.
- DHCS will not reimburse the drug ingredient cost to pharmacies that dispense the monoclonal antibody products since they are supplied free by the federal government.
- DHCS will reimburse the professional dispensing fee.
- Subject to the EUA requirements, DHCS policy does not include administration of these monoclonal antibodies by pharmacies.
- DHCS will not make separate payment for the preparation of monoclonal antibodies for use by another provider or supplier to specialty pharmacies that prepare the product prior to infusion by another provider.

This policy will be updated if providers begin to purchase monoclonal antibody COVID-19 products.

Product Distribution Information

COVID-19 monoclonal antibodies are currently being distributed by the Department of Health and Human Services (HHS) in coordination with state and territorial health departments.

Providers can find public locations that have received shipments via [COVID-19 Therapeutics Locator \(arcgis.com\)](#).

For California, see [Distribution and Ordering of Anti-SARS-CoV-2 Therapeutics](#) on the California Department of Public Health website.

NDC	Label Name	Generic Name	Description	PA Required?	Max Quantity
00173090186	Sotrovimab 500 mg/8 ml VL (EUA)	Sotrovimab	1 vial (500 mg [62.5 mg/mL])	No	1 vial
00310744202	Evusheld 2-vial dose pack (EUA)	Tixagevimab / Cilgavimab	1 carton (2 vials per pack) 1 vial of Tixagevimab 150 mg/1.5 mL (100 mg/mL) 1 vial of Cilgavimab 150 mg/1.5 mL (100 mg/mL)	No	2 cartons (2 vials of each drug)
00002758901	Bebtelovimab 175 mg/2 ml (EUA)	Bebtelovimab	1 vial (175 mg/ 2 mL [87.5 mg/ mL])	No	1 vial

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.